Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.

Clinical pharmacology and therapeutics - 1 Jun 2007

Sjöqvist F, Eliasson E

Abstract excerpt

The development and prospects of conventional therapeutic drug monitoring (TDM) and pharmacogenetic testing as aids in personalized treatment with antidepressants and antipsychotics are described. Our own experience is discussed in relation to international guidelines for rational TDM. Emphasis is put on the usefulness of TDM combined with genotyping of cytochrome P450 2D6 (CYP2D6), the key enzyme involved in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dose-Response Relationship, Drug

Share to Drug Monitoring

Share to Genotype

Share to Pharmacogenetics

Source

Identifiers

PMID: 17392719
DOI: 10.1038/sj.clpt.6100188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.PMID 17392719Read ↗

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.Semantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.Semantic proximity Read ↗

Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry.Semantic proximity Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

Pharmacogenomics and Individualized Drug TherapySemantic proximity Read ↗

The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.Semantic proximity Read ↗

Pharmacogenetics: the therapeutic drug monitoring of the future?Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.Semantic proximity Read ↗

Pharmacogenetics and drug metabolism of newer antidepressant agents.Semantic proximity Read ↗

[Significance of TDM, phenotyping and genotyping for the correct drug dosage].Semantic proximity Read ↗

Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.